On November 19, 2024, Dr. Reddy’s Laboratories announced that the US Food & Drug Administration carried out an inspection at its Active Pharmaceutical Ingredient manufacturing facility (CTO-2) in Bollaram, Hyderabad, from November 13 to 19. Dr. Reddy’s Plans to Address 7 Observations The company stated that it had received a Form 483 with 7 observations …